Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probuphine Re-treatment Study in Opioid Addiction
NCT01262261Phase 3Completed
- Sponsor
- Titan Pharmaceuticals, Inc.
- Start
- Nov 2010
- Primary completion
- Nov 2011
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of buprenorphine implant in opioid use disorder (OUD), sponsored by Titan Pharmaceuticals, Inc. Primary endpoint: Number of subjects with Adverse Events (AEs) at 29 weeks. Started Nov 2010; status: completed.
02
Drugs
buprenorphine implant
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT01262261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01262261.